AdvanCell key facts
as of Oct 2026- Operator of a radiopharmaceutical company intended for developing alpha therapies for cancer patients.
- AdvanCell is valued at approximately $165.0M as of Oct 2026 (last reported valuation).
- It has raised $132.3M; the latest was Grant ($18.0M) in Apr 2025.
- Notable investors include Catalio Capital Management, Morningside Group, SV Health Investors, Brandon Capital, Time BioVentures — 18 tracked in total.
- Status: Privately Held (backing).
AdvanCell's last reported valuation, Jun 2025. Nothing priced has surfaced since.
- ·The complete investor list: 18 names
- ·Watch AdvanCell: the Monday email on marks, rounds and moves
AdvanCell funding rounds
No funding rounds for AdvanCell are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs AdvanCell
18+AdvanCell valuation
AdvanCell's last reported valuation was $165 million in Jun 2025. No priced round, secondary trade or fund mark has surfaced since.
AdvanCell investors
18 investors are on record for AdvanCell, including Catalio Capital Management, Morningside Group, SV Health Investors and Brandon Capital.
About AdvanCell
Operator of a radiopharmaceutical company intended for developing alpha therapies for cancer patients. The company develops alpha-emitting isotopes attached to molecules that deliver cytotoxic radiation directly to tumors at the molecular level to address the significant challenge in targeted therapy that is reliable and scalable to supply, enabling healthcare providers with safe and effective treatment for multiple forms of cancer.
- Sector
- Healthcare
- HQ
- Sydney, Australia
- Founded
- 2019
- Employees
- 76
- Website
- advancell.com.au/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.